Peter Chickering

“$5 million, Medicare pricing, and S&B. So can you bridge us to the good guys back half the year versus last quarter?”

“Can you talk about the ramp of the LDDs in the back half of the year and how to think about the contribution of revenue and EBITDA? Any color of view will be involved in the directs and RASA when it launches in the fall, and how should we think about the overall EBITDA seasonality in 3Q and 4Q?”

“A follow-up on Elizabeth's questions on BLS. Just talk about specifically for early stage development, you know, how the market looks, how the new deals look, you know, like how's your win ratio and how's pricing and how these strategic actions can impact margins in the back half of the year.”

“DC clinics, I think it's sort of down just to make centers. I guess I should be thinking about two key results as a decelerating trend.”

“Can you talk about the emergent versus elective surgeries that you saw on the 2Q and split out between inpatient and outpatient, and what do you think the demand setup is for that in the back half of the year?”